PE20021158A1 - Derivados de sulfonamida como antagonistas del receptor de bradiquinina - Google Patents
Derivados de sulfonamida como antagonistas del receptor de bradiquininaInfo
- Publication number
- PE20021158A1 PE20021158A1 PE2002000401A PE2002000401A PE20021158A1 PE 20021158 A1 PE20021158 A1 PE 20021158A1 PE 2002000401 A PE2002000401 A PE 2002000401A PE 2002000401 A PE2002000401 A PE 2002000401A PE 20021158 A1 PE20021158 A1 PE 20021158A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ilo
- bradiquinin
- indan
- sulfonamide derivatives
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 1,2-DICHLOROPHENYL Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29082701P | 2001-05-14 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021158A1 true PE20021158A1 (es) | 2003-03-03 |
Family
ID=23117717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000401A PE20021158A1 (es) | 2001-05-14 | 2002-05-14 | Derivados de sulfonamida como antagonistas del receptor de bradiquinina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7109203B2 (enExample) |
| EP (1) | EP1389183B1 (enExample) |
| JP (1) | JP4150597B2 (enExample) |
| CN (1) | CN1268610C (enExample) |
| AR (1) | AR035891A1 (enExample) |
| AT (1) | ATE459598T1 (enExample) |
| BR (1) | BR0209386A (enExample) |
| CA (1) | CA2443721A1 (enExample) |
| DE (1) | DE60235536D1 (enExample) |
| ES (1) | ES2340664T3 (enExample) |
| PE (1) | PE20021158A1 (enExample) |
| PT (1) | PT1389183E (enExample) |
| WO (1) | WO2002092556A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| CA2439222C (en) * | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| EP1572678A4 (en) * | 2002-12-19 | 2008-05-07 | Elan Pharm Inc | SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS |
| CA2583185A1 (en) | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| PL1989214T3 (pl) | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
| CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| JP2010502649A (ja) * | 2006-09-01 | 2010-01-28 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋層画像化法中の患者の耐性を増加させるための方法および組成物 |
| JP2011502101A (ja) * | 2006-09-29 | 2011-01-20 | ギリアード・パロ・アルト・インコーポレイテッド | 肺疾患の病歴を有する患者における心筋画像化法 |
| EP2099360A2 (en) * | 2007-01-03 | 2009-09-16 | CV Therapeutics Inc. | Myocardial perfusion imaging |
| AU2009228765B2 (en) * | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| EP2344145A1 (en) * | 2008-09-29 | 2011-07-20 | Gilead Sciences, Inc. | Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods |
| EP2316820A1 (en) | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| SMT201700161T1 (it) * | 2013-06-14 | 2017-05-08 | Dompe Farm Spa | Antagonisti del recettore della bradichinina e composizioni farmaceutiche che li contengono |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE120047C (enExample) * | ||||
| FR2743562B1 (fr) * | 1996-01-11 | 1998-04-03 | Sanofi Sa | Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant |
| WO2001024786A1 (en) * | 1999-05-13 | 2001-04-12 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
| GB9913079D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
-
2002
- 2002-05-13 US US10/475,420 patent/US7109203B2/en not_active Expired - Fee Related
- 2002-05-13 JP JP2002589442A patent/JP4150597B2/ja not_active Expired - Fee Related
- 2002-05-13 BR BR0209386-3A patent/BR0209386A/pt not_active IP Right Cessation
- 2002-05-13 AT AT02742997T patent/ATE459598T1/de not_active IP Right Cessation
- 2002-05-13 PT PT02742997T patent/PT1389183E/pt unknown
- 2002-05-13 AR ARP020101737A patent/AR035891A1/es unknown
- 2002-05-13 CA CA002443721A patent/CA2443721A1/en not_active Abandoned
- 2002-05-13 ES ES02742997T patent/ES2340664T3/es not_active Expired - Lifetime
- 2002-05-13 CN CNB028098900A patent/CN1268610C/zh not_active Expired - Fee Related
- 2002-05-13 WO PCT/EP2002/005240 patent/WO2002092556A1/en not_active Ceased
- 2002-05-13 EP EP02742997A patent/EP1389183B1/en not_active Expired - Lifetime
- 2002-05-13 DE DE60235536T patent/DE60235536D1/de not_active Expired - Fee Related
- 2002-05-14 PE PE2002000401A patent/PE20021158A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1268610C (zh) | 2006-08-09 |
| WO2002092556A1 (en) | 2002-11-21 |
| JP4150597B2 (ja) | 2008-09-17 |
| CA2443721A1 (en) | 2002-11-21 |
| PT1389183E (pt) | 2010-04-26 |
| US7109203B2 (en) | 2006-09-19 |
| EP1389183B1 (en) | 2010-03-03 |
| DE60235536D1 (de) | 2010-04-15 |
| EP1389183A1 (en) | 2004-02-18 |
| US20040127533A1 (en) | 2004-07-01 |
| JP2004528385A (ja) | 2004-09-16 |
| BR0209386A (pt) | 2004-07-06 |
| ATE459598T1 (de) | 2010-03-15 |
| AR035891A1 (es) | 2004-07-21 |
| CN1509269A (zh) | 2004-06-30 |
| ES2340664T3 (es) | 2010-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
| DE60228406D1 (de) | PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS | |
| PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
| PE20040987A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| PE20051146A1 (es) | Compuestos heterociclicos anticitocina | |
| MY146532A (en) | Thiazole derivative | |
| PE20081263A1 (es) | DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO | |
| PE10897A1 (es) | Compuestos benzo fusionados | |
| MX2009013119A (es) | Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio. | |
| PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| PE20060727A1 (es) | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
| PE20030541A1 (es) | Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13 | |
| PE20030930A1 (es) | Derivados de tiazol como antagonistas del receptor npy | |
| PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina | |
| PE20020409A1 (es) | Derivados de 2h-tetrazol-5-il amida como agonistas de receptores de glutamato metabotropico | |
| CO5611136A2 (es) | Derivados de 4-(fenil-(piperidin-4-iliden-metil)-benzamida y su uso para el tratramiento del dolor, ansiedad o desordenes gastrointestinales | |
| PE20050133A1 (es) | Piperazinas sustituidas heterociclicas | |
| YU84901A (sh) | Derivati 4-fenil-pirimidina | |
| PE20081683A1 (es) | Nuevos derivados de sulfonamida | |
| PE20061348A1 (es) | DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa | |
| AR041079A1 (es) | Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |